Researchers launch Phase 1 clinical trial of potential MRSA treatment

Researchers launch Phase 1 clinical trial of potential MRSA treatment
This is a colorized scanning electron micrograph of a white blood cell (blue and brown) interacting with an antibiotic-resistant strain of Staphylococcus aureus (yellow). Credit: NIAID

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. The Phase 1 trial, which will enroll as many as 64 healthy men and women ages 18 to 45, will evaluate the investigational drug's safety as well as how it is broken down and processed in the body. The trial is being conducted by the Massachusetts-based biotechnology company Enanta Pharmaceuticals through contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID funded Enanta's earlier preclinical testing and development of EDP-788.

Infections with bacteria resistant to were first reported in the 1940s, with the earliest cases of MRSA appearing in the 1960s. Since then, MRSA and other antibiotic-resistant infections have become more common in both health care settings and the broader community. EDP-788 belongs to a novel class of antibiotics known as bicyclolides, which were designed to overcome resistance. In laboratory and small animal experiments, EDP-788 and other bicyclolides have demonstrated potent activity against a variety of infectious bacteria, including MRSA.

In the new trial, participants will receive either a single dose of EDP-788 in pill form or a placebo. Two weeks later, a subset of participants will receive a second dose or placebo—either in liquid form, to assess the effect of formulation on absorption into the body; or in pill form along with a meal, to assess the effect of food on absorption. Blood levels of the drug will be measured for three days after receiving each dose, and participants' safety will be monitored for eight to ten days after each dose.

Information about this clinical trial is available at ClinicalTrials.gov using the identifier NCT01999725. For information on the drug development process and NIAID's role, see the NIAID video "How a Drug Becomes a Drug".

add to favorites email to friend print save as pdf

Related Stories

NIH launches trial of investigational genital herpes vaccine

Nov 08, 2013

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

10 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments